Oncology and Carcinogenesis articles for Fudan University, China

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 200

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
10 4.79
Reengineered Albumin-Paclitaxel Nanoparticles Remodeling Tumor Cell Death Pathways for Prevention of Chemotherapy-Induced Breast Cancer Metastasis 1.00
Dual-Powered Nanomotor In Situ Vaccine with Tumor-Confined Penetration and Acidity Neutralization Boosts Stimulator of Interferon Genes-Mediated Immunotherapy 0.92
Muscle-Targeted Nanocomposite Therapy Alleviates Age-Related Sarcopenia via Antioxidant and Metabolic Reprogramming 0.05
Efferocytosis-Mimicking Nanovesicle-Cross-Linked Hydrogel for Dual Immunomodulation and Angiogenesis to Prolong Allogeneic Skin Graft Survival 0.08
Pyroptosis-Inducing Nanoplatform with Plasmonic-Enhanced Phototherapy for Metastasis-Suppressive Cancer Immunotherapy 0.50
Synergizing Ferroptosis Suppressor Protein 1 Gene Silencing and Photodynamic Therapy Based on Photosensitive Lipid Nanoparticles for Colon Cancer Immunotherapy 0.10
Immuno-Initiator Rectifies Immunodeficiency to Restore Immune Function and Potentiate Immunotherapy against IDH Mutant Glioma 0.45
Axially Chlorinated Carbon Nanodots for Hypoxia-Tolerant Neutrophil-Mimicking Photoenzymatic Cascade Therapy against Postoperative Tumor Recurrence 0.64
Self-Driving and Detachable Lab-Microrobots Tailor Drug Delivery for Closed-Loop Stimulation of the Antitumor Immune Cycle 0.07
Disrupting Tumor Lactate Homeostasis to Sensitize Chemo-Immunotherapy Using a Glucose-Disguised Lactate Interceptor 0.98
1 0.54
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2− breast cancer: The LINUXtrial 0.54
4 1.37
Biomimetic Nanoreactor-Driven Synergistic Anti-Glioblastoma Therapy Through Integrated Bioorthogonal Catalysis and Sonodynamic Activation 0.70
Tripartite Cascading Functions of Ultrathin RhMo Nanozymes in Tumor Catalytic Therapy 0.05
Hyaluronic Acid-Coated DNA Nanoflowers as Smart Nanocarriers for Deep Tumor Penetration and Enhanced Gene Therapy in Pancreatic Cancer 0.15
Engineered Ginseng‐Derived Nanovesicles with MCSP Targeting and Mitochondria‐Directed Prodrug Delivery for Synergistic Immunotherapy of Metastatic Melanoma 0.47
5 1.59
Reprogramming Disulfide Reduction in Endoplasmic Reticulum Uncouples Immune Evasion of Pancreatic Cancer 0.63
An Antigen-Capturing Nanoparticle Harnesses the Protein Corona to Enhance Antigenic Immunogenicity and Clonal Diversity against Cancer 0.07
Self-Assembled Two-Dimensional Chiral Meso-Topography Determines the Balance of Cellular and Humoral Immunity Against Tumors 0.75
Optimized Lipid Nanoparticles for Co‐Delivery of mRNA and siRNA Therapeutics in Refractory Liver Cancer 0.03
A Smart DNA Nanoframework Enables Synergistic Photodynamic Therapy of Pancreatic Cancer 0.11
1 0.13
Accurate and Early Diagnosis of NSCLC Using Aberrant Fragmentomic Features of Circulating Cell-Free Mitochondrial DNA. 0.13
3 1.20
Integrated and Ultrafast Multiomics Sample Preparation Workflow for Screening Biomarker Panel of Platelet Biomolecules for Early Diagnosis of HCC 0.78
Single-Cell Raman Spectroscopy Combined with Metabolomics Reveals Distinct Metabolic Profiles in Medulloblastoma Subtypes 0.33
Ultrasensitive eccDNA Detection for Tumor Diagnostics by Using CRISPR/Cas12a-Coupled Nested PCR 0.09
1 0.11
Dual-Interface Nanopore Array Sensor Revealing the Synergistic Oscillations of Lactate Efflux in Cancer Cells 0.11
1 0.73
Palliative Care Educational App for Family Caregivers of Homebound Patients With Incurable Cancer : A Single-Center Randomized Trial. 0.73
1 0.10
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. 0.10
1 0.19
Deep learning analyses of splicing variants identify the link of PCP4 with amyotrophic lateral sclerosis 0.19
1 0.10
Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma 0.10
10 1.55
Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration 0.08
Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways 0.40
Molecular insights into early malignant transition of hepatocellular carcinoma 0.36
Candida albicans synergizes with Fusobacterium nucleatum in colorectal cancer progression via the Flo9-RadD interaction 0.06
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases 0.08
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer 0.24
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study 0.03
Neoadjuvant treatment of IBI310 plus sintilimab in locally advanced MSI-H/dMMR colon cancer: A randomized phase 1b study 0.02
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers 0.03
Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps 0.25
10 4.56
ARID1A Mediates SWI/SNF-Independent Maintenance of Heterochromatin Architecture to Restrain Viral Mimicry and Immunogenicity in Colon Cancer 0.07
KLF5 Activation Promotes Malignant Transformation to Drive Development of Lung Squamous Cell Carcinoma 0.70
Cancer-Associated Fibroblasts Promote Imatinib Resistance in Gastrointestinal Stromal Tumors through PGK1-Mediated Metabolic Reprogramming. 0.88
TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression 0.08
Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer 0.02
Mitochondrial Calcium Uniporter Links Acetyl-CoA Metabolism and H3K27 Acetylation to Maintain Glioblastoma Stem Cells 0.10
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2- Breast Cancer. 0.83
Pancreatic Neuroendocrine Tumors Secrete Apolipoprotein E to Induce Tip Endothelial Cells That Remodel the Tumor–Stroma Ratio and Promote Cancer Progression 0.83
Mannose Enhances Immunotherapy Efficacy in Ovarian Cancer by Modulating Gut Microbial Metabolites 0.92
Perivascular Niche–Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan Treatment 0.13
3 1.65
Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment 0.98
Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance 0.64
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis 0.03
1 0.41
Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML 0.41
1 0.73
Paired patient-derived organoids reveal transcription factor-driven epigenetic remodeling in breast cancer metastasis 0.73
1 0.04
Long-range deployment of tumor-antigen-specific cytotoxic T lymphocytes inhibits lung metastasis of breast cancer 0.04
1 0.02
Environmental PFOS and 6:2 Cl-PFESA Reshape Ferroptosis Vulnerability in Liver Cancer 0.02
7 2.76
Norepinephrine promotes tumour cell aggressiveness and NK cell ferroptosis via ADRB2 in intrahepatic cholangiocarcinoma with perineural invasion 0.93
Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study 0.07
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy 0.02
Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition 0.90
Hypothesis-generating evaluation of multi-armoured oncolytic HSV-1 (VG161) in intrahepatic cholangiocarcinoma: pooled insights from multicentre studies 0.02
Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial 0.19
Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer 0.64
4 1.38
Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy. 0.77
MSR1+ macrophages passivate antitumor immunity by inducing ITM2A+ CD4T exhaustion differentiation. 0.05
NEK7 induced phosphorylation of EGFR on serine 1070 drive the acquired lenvatinib resistance in hepatocellular carcinoma. 0.06
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in hepatocellular carcinoma. 0.50
3 1.99
LATS kinase activity and tumor suppressor function are regulated by a second autophosphorylation site 1.00
Transmembrane BAX inhibitor motif containing 1 Inhibition of lysosomal degradation of TGF-β receptor 1 suppresses cellular senescence and hepatocarcinogenesis 0.10
Vacuole protein sorting 18 (Vps18) suppresses epithelial growth factor receptor (EGFR) expression and lung tumorigenesis 0.89
1 0.46
US-guided Nanosecond Pulsed Electric Field Ablation of Low-risk PTMC: Interim Results of a Prospective Multicenter Study 0.46
2 1.65
EGFR- and HER3-targeted bispecific antibody-drug conjugate demonstrates anti-tumor activity in metastatic castration-resistant prostate cancer 0.65
Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance 1.00
11 1.98
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort 0.03
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial. 0.04
Phase II Study of BCMA Chimeric Antigen Receptor T-Cell Therapy in Patients With Newly Diagnosed Multiple Myeloma Ineligible for or Not Proceeding to Autologous Stem-Cell Transplantation (CAREMM-001). 0.03
Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. 0.23
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.05
Efficacy and Safety of Neoadjuvant TQB2102 in Locally Advanced or Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Randomized, Open-Label, Multicenter, Phase II Trial. 0.50
Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial. 0.14
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.02
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.03
Phase III Study of Mediastinal Lymph Node Dissection for Ground Glass Opacity-Dominant Lung Adenocarcinoma. 0.84
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study. 0.08
3 0.61
MARCO+ macrophages drive immunosuppressive remodeling and metastasis in chemotherapy-associated steatohepatitis 0.07
PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy 0.52
Targeting xanthine oxidoreductase reverses resistance to EGFR tyrosine kinase inhibitors in intrahepatic cholangiocarcinoma 0.03
2 0.10
Surgery versus definitive radiotherapy after induction immunochemotherapy for stage II and III non–small cell lung cancer: A multicenter, pragmatic analysis 0.07
Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management 0.03
4 0.78
Enzyme-Triggered Self-Immobilization of an NIR Prodrug for Tumor-Selective Cancer Vaccination 0.09
Discovering Targetable Conformation of RhoA Mutant by Integrating Native Mass Spectrometry, Ultraviolet Photodissociation, and X-ray Diffraction 0.01
Divergent Syntheses of the Euphorbia Diterpenoids Pepluanol A and Pepluacetal 0.63
Smart Energy-Storing DNA Hydrogel for On-Demand Laser-Free Photoimmunotherapy of Melanoma 0.06
2 0.12
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials 0.10
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.02
5 2.59
Debranching enzyme DBR1-mediated lariat RNA turnover requires ALBA proteins in Arabidopsis 0.88
Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response 0.12
BAG2 releases SAMD4B upon sensing of arginine deficiency to promote tumor cell survival 1.00
Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation 0.10
Mediator regulates transcriptional termination through crosstalk with pre-mRNA 3′ end processing factors 0.49
3 0.44
DNA Nanoflowers Efficiently Encapsulate Photodynamic Agents and CRISPR/Cas9 for Synergistic Pancreatic Cancer Therapy 0.08
Near-Infrared Photothermal-Pyroelectric Coupling (PTPC)-Activated Trace Element Prodrug Nanoplatform for Tumor-Specific Immune Modulation and Therapy 0.13
Nanoshield Architecture Harnessing Neoantigen-Targeting Peptides Enables Durable Post-surgical Glioma Immunotherapy 0.23
1 0.05
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma 0.05
2 0.11
Diet-derived galactose reprograms hepatocytes to prevent T cell exhaustion and elicit antitumour immunity 0.03
YAP maintains the dynamics of TDP-43 condensates and antagonizes TDP-43 pathological aggregates 0.09
1 0.08
Targeting thymine DNA glycosylase induces synthetic lethality in p53-deficient cancers 0.08
36 11.11
Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in -deficient triple negative breast cancer 0.77
The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial 0.06
Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases 0.82
Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial 0.83
Augmented prediction of multi-species protein–RNA interactions using evolutionary conservation of RNA-binding proteins 0.06
Genetic landscape and functional exploration of kidney cancer predisposition in cross-ancestral populations 0.08
ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer 0.71
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer 0.04
X-ray preactivated reversible persistent luminescence enables photodynamic immunotherapy of deep tumors 0.03
Inhibition of the cancer stem cell immune checkpoint SOAT1 suppresses regulatory T cell functions through a trans-cellular 20(S)-Hydroxycholesterol-GPR132 pathway in mice 0.81
Cadonilimab plus chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer: subgroup analyses from the COMPASSION-16 phase 3 trial 0.02
An ultraconserved pseudo 5’ splice site fine-tunes development by regulating alternative splicing within TOR-related pathways 0.09
Eukaryote initiation factor 6 modulates small-cell lung carcinoma plasticity via the integrin-FAK signaling axis 0.02
Cryo-EM structures of light chain fibrils from abdominal fat biopsies of multiple myeloma patients 0.25
Endothelial PDLIM5 promotes tip cell filopodia formation and tumor angiogenesis by regulating ACTN1/ACTN4-dependent actin bundling 0.06
De novo variants in the splicing factor gene are associated with neurodevelopmental disorders 0.01
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma 0.12
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial 0.06
Local therapeutic platform prevents postsurgical GBM recurrence by diminishing GICs and reshaping immunosuppressive microenvironment 0.09
Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial 0.01
Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy 0.05
Automated MRI system for clinically significant prostate cancer detection development validation and real-world implementation 0.04
A moonlighting function of tumoral interleukin-1β precursor promotes metastasis via RACK1-mediated actin remodeling 0.06
Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation 0.50
Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status 0.66
Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs 0.11
αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models 0.06
Direct - mRNA interaction regulates cell proliferation and cancer progression 0.40
CD137L promotes immune surveillance in melanoma via HLTF regulation 0.08
Targeting ALDH16A1 mediated thioredoxin lysosomal degradation to enhance ferroptosis susceptibility in SMARCA4-deficient NSCLC 0.92
CRISPR screening reveals that RNA helicase DDX41 triggers ribosome biogenesis and cancer progression through R-loop-mediated RPL/RPS transcription 0.97
Mogat1 drives metabolic adaptations to evade immune surveillance 0.31
Metabolism archetype cancer cells induce protumor TREM2 macrophages via oxLDL-mediated metabolic interplay in hepatocellular carcinoma 0.39
Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer 0.13
Synthetic carbon-based lanthanide upconversion nanoparticles for enhanced photothermal therapy 0.50
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy in thymic epithelial tumors with pleural spread or recurrence: a prospective, single-arm, phase II study 1.00
1 0.31
Multi-omic analysis of gallbladder cancer identifies distinct tumor microenvironments associated with disease progression 0.31
1 1.00
Tumor-derived branched-chain α-keto acids activate Notch signaling in tumor-associated macrophages to limit immunity 1.00
3 1.09
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 0.06
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial 0.05
Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial 0.99
1 0.22
A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma 0.22
3 1.33
Metabolomic insights into associations between adiposity markers and liver cancer risk: Results from a prospective cohort study and Mendelian randomization analysis 0.07
Consolidative stereotactic radiotherapy for oligo-residual non-small cell lung cancer after first-line chemoimmunotherapy: A single-arm, phase 2 trial from China 0.85
Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial 0.41
8 3.81
Spatial multiomics profiling reveals ZFP36-mediated immunometabolic reprogramming in bladder cancer 0.44
A pharmacovigilance data–driven approach to reveal high fatal adverse events following checkpoint immunotherapy 0.11
Lipid nanoparticle–mediated in vivo generation of panCAR immune cells for solid tumor immunotherapy 1.00
Proteasome stress activates YAP/TAZ through the RAP2–MAP4Ks–LATS1/2 pathway and its therapeutic implications in solid tumors 1.00
USP1–TRAF2 axis–regulated mortalin stability mediates chemoresistance by disrupting calcium transport in peripheral T-cell lymphoma 0.79
CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma 0.13
The pathogenic factor of ZC4H2-associated rare disorder is a postsynaptic regulator for synaptic activity and cognitive function 0.17
Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy 0.17
1 0.73
Mesorectal Fascia Involvement by Tumor Deposits or Extramural Vascular Invasion at MRI Predicts Prognosis in Rectal Cancer. 0.73
1 0.18
Dynamic U2AF cycling defines two phases of cotranscriptional pre-mRNA splicing 0.18
8 1.54
Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma 0.03
Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors 0.07
Impaired nitrogenous waste clearance promotes hepatocellular carcinoma 0.05
Targeting RRM2 with dual-modal theranostic smart nanoresponder overcomes osimertinib resistance and triggers immune remodeling in NSCLC 0.03
Liver regeneration–associated hepatocellular YAP1 activation prevents colorectal cancer liver metastasis through glutamine competition 0.54
HLF transactivates TFEB to promote gallbladder cancer stem cells’ self-renewal and determines tumor response to distinct therapies 0.10
Engineering hybrid nanoparticles for targeted codelivery of triptolide and CYP3A4-siRNA against pulmonary metastatic melanoma 0.61
Targeting tumor-associated CCR2+ macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation 0.11
6 2.64
Targeting RBPMS selectively eliminates FOXO1-mediated stem cell signatures in mouse models of acute myeloid leukemia 0.04
Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome 0.03
Targeting the origins of multiple myeloma along hematopoietic stem cell lymphoid lineage differentiation 0.07
Cholesterol desensitizes the response of endometrial cancer to progestin by attenuating progestin signaling 0.89
Interferon-induced senescent CD8+ T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancer 1.00
Proteogenomic characterization reveals that lipid droplet formation promotes esophageal squamous cell cancer progression 0.62
1 1.00
Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial 1.00
4 0.40
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial 0.26
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China 0.03
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial 0.06
10 1.78
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB–IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study 0.04
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial 0.07
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.04
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study 0.04
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 0.06
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial 0.04
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.04
Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study 0.90
Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study 0.53
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial 0.02
8 0.97
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer 0.05
First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations 0.03
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer 0.03
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma 0.71
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.03
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.03
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC 0.03
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.05
1 0.89
The Arabidopsis histone methylation reader MRG2 interacts with eIF4A3 to regulate alternative splicing and circadian rhythms 0.89

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.